Linh Do, MD
Urogynecology and Reconstructive Pelvic Surgery · Houston, TXNPI 1073976114
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.1%), travel and lodging and education — rather than concentrated in one kind of arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 21.8%. Reporting peaked in 2023 at $5,533 and has fallen 77.1% since, to $1,265 in 2025.
Across 154 payments — averaging $70.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$2K
- Intuitive Surgical$2K
- Coloplast$2K
- Boston Scientific$2K
- Medtronic$1K
- Sumitomo Pharma America, Inc.$363
- plus $1K from 21 others
What the payments were for
- Travel & lodging$3,75535%
- Food & beverage$5,95655%
- Education$1,10010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 24 | $2,362 |
| Intuitive Surgical | 9 | $2,304 |
| Coloplast | 23 | $1,793 |
| Boston Scientific | 13 | $1,513 |
| Medtronic | 21 | $1,290 |
| Sumitomo Pharma America, Inc. | 21 | $363 |
| Progenics Pharmaceuticals, Inc. | 5 | $145 |
| Teleflex LLC | 3 | $115 |
| AbbVie | 5 | $97 |
| Bayer | 3 | $96 |
| Dendreon Pharmaceuticals LLC | 3 | $84 |
| Johnson & Johnson(2 entities) | 3 | $70 |
| AstraZeneca | 1 | $65 |
| Coopersurgical, Inc. | 2 | $62 |
| Myriad Genetic Laboratories, Inc. | 2 | $57 |
| Verity Pharmaceuticals Inc. | 2 | $51 |
| Femselect Inc. | 1 | $51 |
| Merck | 2 | $49 |
| Caldera Medical, Inc | 2 | $33 |
| Biomarin Pharmaceutical Inc. | 1 | $31 |
| ABC Home Medical Supply, Inc. | 2 | $31 |
| Novo Nordisk | 1 | $30 |
| Polynovo North America LLC | 1 | $30 |
| Bluewind Medical | 1 | $27 |
| Dilon Technologies, Inc. | 1 | $22 |
| Cook Medical LLC | 1 | $19 |
| Antares Pharma, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$1,628
- ALTIS$1,323
- Da Vinci Surgical System$1,237
- DAVINCI XI$1,000
- INTERSTIM$898
- Solyx SIS System$104
How this compares
$10,811 in reported general payments places this provider in the 80th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.
See all urogynecology and reconstructive pelvic surgery providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 96 | $98,982 |
| MyrbetriqMirabegron | 37 | $28,547 |
| Estradiol | 247 | $14,008 |
| Trospium Chloride ErTrospium Chloride | 30 | $3,751 |
| Solifenacin Succinate | 21 | $3,057 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 96 | $1,508 |
| Cephalexin | 33 | $257 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 50 | $173 |
| Oxycodone Hcl | 42 | $87 |
| Fluconazole | 17 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $363 | $98,98296 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.
Other urogynecology and reconstructive pelvic surgery in Houston
- Gazala SiddiquiHouston$81K
- Fiona LindoHouston$66K
- Peter LotzeHouston$48K
- Oluwarotimi NetteyHouston$19K
- Christine PanHouston$11K
- Apurva PancholyHouston$10K
- Danielle AntoshHouston$8K
- Khadijah EidHouston$8K
- Emily RutledgeHouston$5K
- Sarah RozyckiHouston$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.